In a landmark industry transaction, Evotec signs agreement with Sandoz, resulting in payments potentially over US$ 650 m plus royalties on portfolio of up to 10 biosimilar molecules Transaction showcases Evotec's unique

In a landmark industry transaction, Evotec

signs agreement with Sandoz, resulting in payments potentially over US$ 650 m plus royalties on portfolio of up to 10 biosimilar

Germany, 04 November 2025:

SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ: EVO),

a life science company that is pioneering the future of drug discovery and development, today announced the successful signing of the

sale of the Just - Evotec Biologics Toulouse site to Sandoz AG (SIX: SDZ / OTCQX: SDZNY), a global leader in generic

and biosimilar medicines.

Under the landmark transaction,

Sandoz will acquire 100% of Just - Evotec Biologics EU plus an indefinite technology license to Evotec's continuous manufacturing

platform technology for a payment of approximately US$ 350 m in cash. The agreement includes additional license fees and development

revenues including success-based milestones, adding up to more than US$ 300 m in the coming years. In

the future, Evotec expects to benefit from royalties on a portfolio of up to ten biosimilars in technical and early development targeting

a net originator sales market of more than US$ 90 bn.

With this acquisition, Sandoz will gain access to Evotec's proprietary

platform for integrated development and advanced continuous manufacturing of biologics via an indefinite license.

contract signature follows the announcement in July of a non-binding term-sheet agreement on 30 July 2025.

Both parties aim to close the transaction in Q4 2025 subject to meeting closing conditions including foreign direct investment (FDI) clearance

by the French authorities. The transaction will have a significant positive impact on Evotec's revenue mix, profit margins, and

capital efficiency immediately after closing.

Dr Christian Wojczewski, Chief Executive Officer of Evotec, said:

"This is a transformative milestone for Evotec as we further

leverage Just - Evotec Biologics' capabilities and position the company as a scalable technology provider. With our unique

offering, we are expanding the scope of addressable partners and shaping a new segment in the biologics manufacturing market in a very

capital efficient way. Additionally, with this transaction, Evotec is delivering on its asset lighter strategy, sharpening its focus on

its core strengths, and is well on track for sustainable and profitable growth."

Dr Linda Zuckerman, EVP and Global Head of Just - Evotec Biologics,

"Sandoz's acquisition of Just - Evotec Biologics'

Toulouse site is a powerful endorsement of our pioneering J.POD platform and its potential to revolutionize biologics manufacturing. This

strategic transaction empowers Sandoz to leverage our advanced perfusion-based continuous manufacturing technology, progressing our shared

mission to expand global access to affordable, high-quality biosimilars. We are proud to see our innovation continue to have a transformative

impact for patients around the world."

After closing of the transaction, Evotec will continue to serve our

customers in the U.S. and Europe with capacity for molecular design, upstream, downstream, analytical and formulation development as well

as First-In-Human to commercial biologics GMP manufacturing.

Evotec confirms guidance for full-year 2025 and its Outlook 2028

For the current fiscal year, the Company expects revenues in the range

of 760 - 800 m (2024: 797.0 m);

R&D expenditures are expected in a range of 40 -

50 m (2024: 50.8 m);

Adjusted EBITDA1 is expected to reach 30 -

50 m (2024: 22.6 m).

Outlook 2028 remains unchanged with a targeted Group revenue CAGR2024-2028

in a range of 8 - 12% and an expected adj. EBITDA margin above 20% by 2028.

Excluding potential costs related to the transformation program in 2025

CAGR: Compound annual growth rate

Evotec is a life science company that is pioneering the future of drug discovery and development. By integrating

breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure - faster,

smarter, and with greater precision.

Our expertise spans small molecules, biologics, cell therapies

and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling.

With flexible partnering models tailored to our customers'

needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings

range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence

with operational agility.

Through Just - Evotec Biologics, we redefine biologics

development and manufacturing to improve accessibility and affordability.

With a strong portfolio of over 100 proprietary R&D assets,

most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and

global team of more than 4,800 experts operates from sites in Europe and the U.S., offering complementary technologies and services as

@Evotec and LinkedIn.

This announcement contains forward-looking statements concerning future events, including the proposed offering

and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate,"

"expect," "intend," "may," "might," "plan," "potential," "should,"

"target," "would" and variations of such words and similar expressions are intended to identify forward-looking

statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D

expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable

by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These

statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to

significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations

or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change

in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

For further information,

EVP Head of Global Investor Relations & ESG